Orexigen appoints new Vice President of Sales and adds eight new employees – April 25, 2016

This morning, Orexigen announced the appointment of Ms. Beth Eastland as Vice President of Sales and an additional eight employees, as the company prepares to assume full US commercialization of Contrave (naltrexone/bupropion extended-release). Prior to joining Orexigen, Ms. Eastland led sales teams for primary care, specialty and hospital products, and managed multiple product launches at Merck. As Orexigen aims to pick up its feet from its following its recent separation from Takeda and CVOT termination, we hope that Ms. Eastland and her team can bring new ideas and insight as to Orexigen as they begin efforts to commercialize Contrave in an efficient and cost-effective manner.